CorMedix Inc. (19KA)

Overview

CorMedix Inc. is a biopharmaceutical company committed to the development and commercialization of novel therapeutic products aimed at the prevention and treatment of infectious and inflammatory diseases, primarily in the United States. Originally founded as Picton Holding Company, Inc., the organization underwent a name change to CorMedix Inc. in January 2007, symbolizing a focused shift towards its core mission in the biopharmaceutical arena. Incorporated in 2006, CorMedix has established its operational base in Berkeley Heights, New Jersey, from where it spearheads its research, development, and commercialization efforts. The company's strategic initiatives are directed towards addressing the unmet medical needs of patients, particularly those suffering from kidney failure, through innovative solutions designed to enhance patient care and outcomes.

Products and Services

CorMedix Inc. is actively involved in the development and prospective commercialization of a leading product candidate, alongside engagement in research aimed at expanding its product portfolio. Detailed below are the key focus areas of its product development efforts:

• DefenCath: CorMedix's flagship product candidate, DefenCath, is an antimicrobial catheter lock solution designed to significantly reduce the incidence of catheter-related bloodstream infections among adult patients with kidney failure. This innovative solution represents a proactive approach to healthcare, aiming to improve patient outcomes and quality of life by combating the challenges posed by bloodstream infections, which are a common complication in patients undergoing dialysis treatments.